Selective TYK2 Inhibitor Compounds for Reduced JAK Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK inhibitors lack selectivity for TYK2 over other JAK family members, leading to undesirable side effects and a narrow therapeutic index in treating autoimmune and inflammatory diseases.
Innovation Solution
Development of compounds that act as selective TYK2 inhibitors, targeting specific domains of the TYK2 kinase to modulate cytokine signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pan-JAK inhibitors or modestly selective inhibitors are used, then broad JAK family coverage is achieved, but selectivity for specific JAK members deteriorates leading to undesirable side effects
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that interact with unique structural characteristics of individual JAK family members. The compounds are engineered to recognize and bind selectively to specific residues or structural motifs present in particular JAK isoforms (JAK1, JAK2, JAK3, or TYK2) while avoiding binding to other family members, thereby achieving localized inhibition with high selectivity and reduced off-target effects.
Solution Approach 2:
The patent employs parameter changes by systematically modifying chemical parameters of the inhibitor molecules, including substituent types, positions, and stereochemistry, to optimize selectivity for specific JAK family members. By varying these chemical parameters, the invention achieves differential binding affinities across the JAK family, enabling selective inhibition that improves the therapeutic index by reducing side effects associated with pan-JAK blockade.
2Measurement precision
If selective TYK2 inhibitors are developed, then selectivity for specific JAK member is improved, but complexity of inhibitor design increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules or pharmacophoric elements, each responsible for specific interactions with target residues in the JAK binding site. This modular design approach allows systematic optimization of selectivity by independently tuning each segment's properties while maintaining overall molecular coherence, thereby managing design complexity through structured componentization.
Solution Approach 2:
The patent employs intermediary strategies by using structure-activity relationship (SAR) studies and computational modeling as intermediate tools to guide the optimization process. These intermediaries facilitate the translation of selectivity requirements into concrete molecular design decisions, bridging the gap between desired selectivity outcomes and actual inhibitor structures, thereby reducing overall design complexity through systematic intermediate analysis.
Data Source
AI summary
This disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof, in which all of the variables in Formula (I) are as defined in the application. The compounds of this disclosure are capable of inhibiting the activity of tyrosine kinase 2 (TYK2). The disclosure further provides methods of preparing the compounds of the disclosure, and methods for their therapeutic use.